Dapagliflozin, a novel anti-diabetic drug may have the risk of causing breast and bladder cancer.
FDA Reviewers Flag Cancer Risk in Diabetes Drug
WASHINGTON — FDA reviewers said the novel diabetes drug dapagliflozin appears effective at treating diabetes, but may pose breast and bladder cancer risks as well as liver toxicity.
The FDA’s Endocrinologic and Metabolic Advisory Committee will meet Tuesday vote whether the drug — which is the first of its kind to go before an FDA panel — should be approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin is an inhibitor of the sodium glucose cotransporter-2 (SGLT2) which works by increasing renal glucose elimination, allowing more sugar to be excreted with urine rather than being absorbed into the bloodstream.